pyrroles has been researched along with Carcinoma, Non-Small Cell Lung in 114 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.88) | 18.2507 |
| 2000's | 31 (27.19) | 29.6817 |
| 2010's | 69 (60.53) | 24.3611 |
| 2020's | 13 (11.40) | 2.80 |
| Authors | Studies |
|---|---|
| He, KM; Pu, JT; Teng, ZY; Wu, YF; Zhang, DG; Zhang, T | 1 |
| Kida, Y; Koshikawa, N; Lin, J; Nagase, H; Shinozaki, Y; Takenaga, K; Tsuji, K; Watanabe, T; Yamamoto, S | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Addeo, A; Alborelli, I; Calgua, B; Fernandez, E; Früh, M; Haefliger, S; Holer, L; Jermann, PM; Joerger, M; Mach, N; Mark, M; Mauti, L; Rothschild, SI; Savic-Prince, S; Schneider, M; Waibel, C | 1 |
| He, J; Luo, L; Xu, S; Yang, F; Zhu, W | 1 |
| Bender, S; Boix, O; Cassier, PA; Cathomas, R; Cho, BC; Ellinghaus, P; Gajate, P; Grevel, J; Joerger, M; Navarro, A; Nogai, H; Nogova, L; Ocker, M; Park, SH; Penel, N; Rajagopalan, P; Richly, H; Sayehli, CM; Schostak, M; Schuler, M; Soo, RA; Tai, D | 1 |
| Jia, X; Liu, X; Wang, L; Wei, A; Zhang, K | 1 |
| Chen, S; Duan, P; Ren, Y | 1 |
| Ilhan, R; Ince-Yardimci, A; Kara, P; Kirmizibayrak, PB; Kivrak, E; Yilmaz, S | 1 |
| Fu, H; Fu, L; Li, Y; Lou, L; Quan, H; Zhang, M | 1 |
| Dominici, C; Masson, JY; Raynal, NJ; Richard, S; Sesma-Sanz, L; Sgarioto, N; Yu, Z | 1 |
| Fan, D; Qu, S; Yang, Y; Yu, S | 1 |
| Chai, Y; Chen, H; He, Y; Huang, R; Li, W; Li, Y; Ma, L; Xia, Z; Yu, Q; Zhou, X | 1 |
| Dai, B; Liu, R; Ma, Y; Wang, W; Zhan, Y; Zhang, D; Zhang, Y | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Gu, Y; Hong, H; Lei, YY; Lu, CG; Sheng, SY; Tang, YY; Zhang, YQ; Zou, JY | 1 |
| Jia, W; Liu, Y; Min, L; Qiankun, Z; Sun, W; Wang, WH; Wu, D; Yang, H; Yang, Y; Zhang, H; Zhang, J; Zhang, Y | 1 |
| Belani, CP; Liu, X; Rice, SJ; Wang, HG | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K | 1 |
| Bora-Singhal, N; Chellappan, SP; Kroeger, J; Laklai, H; Singh, S | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Devarakonda, S; Gopalan, PK; Govindan, R; Waqar, SN; Williams, K | 1 |
| Asmar, L; Boehm, KA; Bradie-Muller, SJ; Gluck, L; Mueller, SE; Reynolds, C; Spira, AI; Zhan, F | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Ding, J; Li, X; Meng, LH; Tong, LJ | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Han, BH; Huang, JQ; Jiang, LY; Li, SQ; Liu, YR; Yao, YH; Zhang, JL; Zhang, W; Zhao, YZ; Zhu, W | 1 |
| Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C | 1 |
| Gandhi, L; Heist, RS; Hodgson, L; Otterson, GA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X; Watson, P | 1 |
| Yaqub, F | 1 |
| Agorreta, J; Ajona, D; Casanovas, O; Larrayoz, M; Montuenga, LM; Pajares, MJ; Pio, R; Zudaire, I | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Behnam-Motlagh, P; Brenner, C; Castedo, M; Garcia, P; Kohno, K; Kroemer, G; Lissa, D; Michels, J; Obrist, F; Vitale, I; Wu, GS | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Billingham, LJ; Buller, R; Carr, TH; Crack, LR; Hollingsworth, SJ; Middleton, G; Popat, S; Swanton, C; Walker, I; Wherton, D | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Almaden, C; Bailey, S; Baxi, S; Behenna, D; Cheng, H; Cho-Schultz, S; Dalvie, D; Dinh, DM; Edwards, MP; Feng, JL; Ferre, RA; Gajiwala, KS; Hemkens, MD; Jackson-Fisher, A; Jalaie, M; Johnson, TO; Kania, RS; Kath, JC; Kephart, S; Lafontaine, J; Liu, KK; Liu, Z; Lunney, B; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Ornelas, MA; Orr, ST; Pairish, M; Planken, S; Ren, S; Richter, D; Ryan, K; Sach, N; Shen, H; Smeal, T; Solowiej, J; Sutton, S; Tran, K; Tseng, E; Vernier, W; Walls, M; Wang, S; Weinrich, SL; Xin, S; Xu, H; Yin, MJ; Zhou, R; Zientek, M | 1 |
| Bao, Y; Chen, Q; Feng, W; Guo, H; Lu, Y; Sun, X; Wang, X | 1 |
| Bao, YX; Deng, HB; Deng, LL; Guo, Y; Lu, CL; Lu, X; Zhao, XD | 1 |
| Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
| Liu, K; Ma, J; Wu, K; Xu, Z; Zhao, Z | 1 |
| Ji, SM; Li, JY; Li, L; Lu, W; Mou, ZZ; Ren, YP; Wang, LJ; Yuan, Y; Zhou, SP; Zhou, TY | 1 |
| Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF | 1 |
| Babu, N; Balaji, SA; Chang, X; Chatterjee, A; Datta, KK; Gowda, H; Izumchenko, E; Nanjappa, V; Pandey, A; Patil, AH; Prasad, TS; Puttamallesh, VN; Radhakrishnan, A; Raja, R; Rangarajan, A; Renuse, S; Sahasrabuddhe, NA; Sidransky, D; Solanki, HS; Syed, N | 1 |
| Kurzrock, R; Stewart, DJ | 1 |
| Hao, F; Li, J; Lu, W; Wang, L; Wang, S; Xue, J; Zhou, T; Zhu, X | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Gettinger, S | 1 |
| Socinski, MA | 1 |
| Borgman, CL; Brandstetter, KA; Chirieac, LR; Gandhi, L; Li, D; McDermott, U; McNamara, KL; Padera, RF; Settleman, JE; Wong, KK | 1 |
| Horn, L; Sandler, AB | 1 |
| Ames, RY; Brannigan, BW; Erlander, MG; Greninger, P; Haber, DA; Iafrate, AJ; Lee, DY; Lucien, L; Ma, XJ; Maheswaran, S; McCutcheon, K; McDermott, U; Milano, R; Settleman, J; Sharma, SV; Stubbs, H; Tam, A; Ulkus, LE | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Burrell, RA; Swanton, C | 1 |
| Atkins, J; Brahmer, J; Burgess, R; Chao, R; Govindan, R; Novello, S; Pallares, C; Rosell, R; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L; Wang, E | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P | 1 |
| Bao-Hui, H; Hui-Min, W; Ping, G; Wei-Min, W | 1 |
| Kelleher, FC; McDermott, R | 1 |
| Bourhis, J; De la motte Rouge, T; Deutsch, E; Dorvault, N; Loriot, Y; Mordant, P; Soria, JC | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Chen, YL; Fang, Z; Hua, KF; Lam, Y; Liao, PC; Wu, SH; Yang, FL; Yang, YL | 1 |
| Muto, A; Neri, B; Politi, L; Rangan, S; Tassi, R; Vannini, A | 1 |
| Chen, Z; Jin, H; Lei, Y; Luo, H; Su, C; Wang, T; Zhong, B; Zhuang, M; Zou, J | 1 |
| Jiang, Z; Wang, D; Zhang, L | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Abrey, L; Camps, C; Chao, RC; Grossi, F; Mazieres, J; Novello, S; Patyna, S; Scagliotti, G; Thall, A; Usari, T; Vernejoux, JM; Wang, Z | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Pan, F; Pan, Y; Tian, J; Zhang, X; Zhang, Y | 1 |
| Blais, N; Camidge, DR; Canil, C; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; McWilliam, M; Ruiz-Garcia, A; Thall, A; Tye, L; Zhang, K | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A | 1 |
| An, Y; Chen, J; Li, X; Liu, B; Pan, Y; Tie, L; Yang, J; Yuan, J; Zhang, J | 1 |
| An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J | 1 |
| An, Y; Chen, J; Hou, J; Li, X; Liu, J; Yue, L; Zhang, J; Zhang, X | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Aguilar, A; Bai, L; Chen, J; Liu, L; McEachern, D; Meagher, JL; Stuckey, JA; Wang, S; Yang, CY; Zhou, H | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Doebele, RC; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Kummer, G; Schultheis, B; Strumberg, D | 1 |
| Baselga, J; Hammond, LA | 1 |
| Curran, WJ | 1 |
| Bajo, AM; Halmos, G; Hebert, F; Nagy, A; Schally, AV; Szepeshazi, K; Szereday, Z | 1 |
| Bonomi, P | 1 |
| Cao, C; Choy, H; Freeman, ML; Morrow, JD; Saha, D; Sekhar, KR | 1 |
| Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Kenji, Y; O'reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Ganti, AK; Potti, A | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Herbst, RS | 1 |
| Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Haura, EB; Li, J; Viallet, J | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Scagliotti, GV | 1 |
| Adams, VR; Leggas, M | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Lee, CB; Socinski, MA | 1 |
| Buhl, R; Fischer, B | 1 |
| Carter, SK | 1 |
| Halmos, G; Hebert, F; Kiaris, H; Nagy, A; Schally, AV; Szepeshazi, K | 1 |
| Akimoto, H; Hitaka, T; Miwa, T; Nomura, H | 1 |
21 review(s) available for pyrroles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Pyrrole-based EGFR inhibitors for the treatment of NCSLC: Binding modes and SARs investigations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles | 2023 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult | 2016 |
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Neovascularization, Pathologic; Pyrroles; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
The current status and evolving role of sunitinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Chromosomes, Human, Pair 2; Drug Synergism; Gene Amplification; Humans; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Mutation; Neoplasms; Neuroblastoma; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1 | 2010 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Angiostatins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose Fractionation, Radiation; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Esophageal Neoplasms; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Laryngeal Neoplasms; Lung Neoplasms; Lymphokines; Male; Membrane Proteins; Neoplasms; Peptide Fragments; Plasminogen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
32 trial(s) available for pyrroles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Thiophenes | 2022 |
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Topics: Acute Kidney Injury; Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Diarrhea; Fatigue; Female; Humans; Hyperphosphatemia; Hypoglycemia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Vomiting | 2019 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2013 |
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indoles; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sunitinib; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Young Adult | 2013 |
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Pyrroles; Taxoids | 2014 |
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrroles; Remission Induction; Salvage Therapy; Sunitinib; Survival Rate | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pemetrexed; Prostaglandins; Pyrroles; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Translational Research, Biomedical; United Kingdom | 2015 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2011 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Proteasome Inhibitors; Pyrroles; Vorinostat | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib | 2013 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
61 other study(ies) available for pyrroles and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Transient receptor potential vanilloid 4 promotes the growth of non-small cell lung cancer by regulating Foxp3.
Topics: A549 Cells; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Morpholines; Pyrroles; Sulfonamides; TRPV Cation Channels | 2022 |
Trilaciclib (Cosela) for prevention of chemotherapy-related myelosuppression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum Compounds; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Suppression of non-small-cell lung cancer A549 tumor growth by an mtDNA mutation-targeting pyrrole-imidazole polyamide-triphenylphosphonium and a senolytic drug.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Mitochondrial; Humans; Imidazoles; Lung Neoplasms; Mutation; Nylons; Pyrroles; Senotherapeutics | 2022 |
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Indoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Pyrroles; Pyrrolidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Biomimetics; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Drug Stability; Humans; Indoles; Lung Neoplasms; Male; Mice, Inbred C57BL; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Solubility; Xenograft Model Antitumor Assays | 2020 |
Aptamer-based electrochemical biosensing strategy toward human non-small cell lung cancer using polyacrylonitrile/polypyrrole nanofibers.
Topics: A549 Cells; Acrylic Resins; Aptamers, Nucleotide; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Dielectric Spectroscopy; Electrodes; HeLa Cells; Humans; Limit of Detection; Lung Neoplasms; Nanofibers; Polymers; Pyrroles | 2020 |
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2021 |
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA Damage; Drug Synergism; Enzyme Inhibitors; Ethylenediamines; Humans; Lung Neoplasms; Protein-Arginine N-Methyltransferases; Purine-Nucleoside Phosphorylase; Pyrroles | 2021 |
Pyoluteorin Induces Apoptosis and Autophagy in NSCLC Cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phenols; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2021 |
The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2021 |
Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indoles; Inflammation Mediators; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cytokines; Female; Glycogen Synthase Kinase 3 beta; Humans; Immunologic Memory; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pyrimidines; Pyrroles; Wnt Signaling Pathway | 2018 |
Autophagy Inhibition Enhances SPCA-1 Cell Proliferation Inhibition Induced by By-1 from the Stout Camphor Medicinal Mushroom, Taiwanofungus camphoratus (Agaricomycetes).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Agaricales; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Humans; Lung Neoplasms; Pyrroles | 2018 |
EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Humans; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Oncogene Protein v-akt; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2019 |
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Janus Kinases; Killer Cells, Natural; Ligands; Lung Neoplasms; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT Transcription Factors; Tumor Cells, Cultured | 2019 |
βArrestin-1 and Mcl-1 modulate self-renewal growth of cancer stem-like side-population cells in non-small cell lung cancer.
Topics: Animals; Arrestins; beta-Arrestins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Lung; Lung Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2013 |
Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; Sunitinib; Tissue Culture Techniques; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Receptor, ErbB-2; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
MCL-1 dependency of cisplatin-resistant cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Pyrroles; RNA Interference | 2014 |
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
A two kinase-gene signature model using CDK2 and PAK4 expression predicts poor outcome in non-small cell lung cancers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 2; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; p21-Activated Kinases; Pyrazoles; Pyrroles; Tissue Array Analysis; Treatment Outcome | 2016 |
Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indoles; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib; TNF-Related Apoptosis-Inducing Ligand | 2016 |
MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
Topics: Antineoplastic Agents; bcl-2 Homologous Antagonist-Killer Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2016 |
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Dosage Calculations; Drug Synergism; Erlotinib Hydrochloride; Female; Indoles; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
[Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclobutanes; Cytoskeletal Proteins; Heterografts; Humans; Lung Neoplasms; Lymph Nodes; Male; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Pyrroles; Random Allocation; RNA, Messenger; Sulfides; Transplantation, Heterologous; Tumor Burden | 2016 |
Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; p21-Activated Kinases; Phosphorylation; Proteome; Pyrazoles; Pyrroles; rac1 GTP-Binding Protein; RNA, Small Interfering; Signal Transduction; Smoke; Tobacco Products | 2016 |
Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dopamine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Genetic Engineering; Immunohistochemistry; Indoles; Lung Neoplasms; Mice; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib | 2009 |
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Amplification; Gene Expression Profiling; Humans; Indoles; Ligands; Lung Neoplasms; Lymphokines; Platelet-Derived Growth Factor; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma; RNA, Small Interfering; Sunitinib | 2009 |
Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung Neoplasms; Precision Medicine; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Research Design; Sunitinib; Treatment Outcome | 2010 |
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Screening Assays, Antitumor; ErbB Receptors; Exons; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Piperidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sequence Deletion; Transplantation, Heterologous; Triazines | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Synthesis and biological evaluation of polyenylpyrrole derivatives as anticancer agents acting through caspases-dependent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Polyenes; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2010 |
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Topics: Adult; Aged; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Enzyme Activators; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prostaglandins E; Protein Kinase C; Pyrroles; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A; Xanthones | 2011 |
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cells, Cultured; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Time Factors | 2011 |
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Topics: Animals; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Cell Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; NADPH Oxidases; Protein Transport; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2012 |
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Xenograft Model Antitumor Assays | 2012 |
Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Interferon-gamma; Lung Neoplasms; Mice; Organ Specificity; Pyrroles; rhoA GTP-Binding Protein | 2012 |
Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Transplantation; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Tumor Burden | 2012 |
Sarcomatoid non-small cell lung cancer responding to sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome | 2013 |
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Division; Cytotoxins; Doxorubicin; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Mice; Mice, Nude; Pyrroles; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Down-Regulation; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indoles; Isoenzymes; Lung Neoplasms; Membrane Proteins; NADPH Oxidases; Prostaglandin-Endoperoxide Synthases; Pyrroles; Superoxides; Tetradecanoylphorbol Acetate | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Animal; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Survival Rate | 2004 |
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Humans; Immunoprecipitation; Indoles; Lung Neoplasms; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Tetrazolium Salts; Thiazoles | 2008 |
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2007 |
Off-label uses of sorafenib and sunitinib.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Digestive System Neoplasms; Drug Approval; Female; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Humans; Indoles; Male; Melanoma; Neoplasms, Squamous Cell; Product Labeling; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Clinical strategy for the development of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Disease Progression; Drug Evaluation; Drug Resistance, Neoplasm; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Lymphokines; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Doxorubicin; Lung Neoplasms; Male; Mice; Mice, Nude; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2001 |
Novel pyrrolo[2,3-d]pyrimidine antifolates: synthesis and antitumor activities.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line; Chemical Phenomena; Chemistry; Folic Acid Antagonists; Humans; Lung Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship | 1991 |